Lisbeth Salling
Copenhagen University Hospital, Rigshospitalet, University of Copenhagen
Papers
3
Total Citations
52
H-Index
2
About
Lisbeth Salling is a clinical researcher at the forefront of urologic oncology, specializing in the surgical management of bladder cancer. Her work centers on a critical, unanswered question: does robot-assisted radical cystectomy (RARC) offer tangible advantages over the traditional open approach (ORC)? Salling’s major contribution is the BORARC trial, a landmark double-blinded, randomised feasibility study that pioneered a novel methodology—blinding both patients and care providers to the surgical technique. This rigorous design, detailed in her most-cited paper (41 citations), addresses a fundamental bias in surgical trials and sets a new standard for comparative effectiveness research. Her work extends to perioperative optimization, as shown in her investigation of plasma pro-atrial natriuretic peptide (proANP) as a biomarker for fluid balance during cystectomy (9 citations). By challenging dogma and implementing innovative trial designs, Salling is directly shaping safer, more evidence-based surgical care for bladder cancer patients. Her research is not just about comparing tools; it is about refining the entire perioperative pathway, from fluid management to recovery protocols, ensuring that the next generation of surgical decisions is grounded in robust, unbiased data.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3